224
Participants
Start Date
September 28, 2021
Primary Completion Date
September 30, 2023
Study Completion Date
September 30, 2023
Tenecteplase
Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
Best treatment arm
Huashan Hospital, Shanghai
Puer People's Hospital
UNKNOWN
Shanghai 6th People's Hospital
OTHER
Hexigten Traditional Chinese and Mongolian Medicine Hospital
UNKNOWN
Yangpu Hospital, School of Medicine, Tongji University
UNKNOWN
The First Affiliated Hospital of Shanxi Medical University
OTHER
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine
UNKNOWN
Linyi People's Hospital
OTHER
Shanghai 10th People's Hospital
OTHER
Nanshi Hospital of Nanyang
UNKNOWN
Fudan University
OTHER
Xuzhou Medical University Affiliated Hospital of Huaian
UNKNOWN
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
UNKNOWN
The First Affiliated Hospital of Soochow Medical University
UNKNOWN
Affiliated Haian People's Hospital of Nantong University
UNKNOWN
First Affiliated Hospital of Harbin Medical University
OTHER
the Third Hospital of Mianyang
UNKNOWN
Zhejiang Province People's Hospital
UNKNOWN
Shanghai East Hospital
OTHER
The Central Hospital of Jiaozuo Coal Group
UNKNOWN
Huizhou Municipal Central Hospital
OTHER
Zhejiang University
OTHER
The Second Affiliated Hospital of Chongqing Medical University
OTHER
Ningbo No. 1 Hospital
OTHER
Huashan Hospital
OTHER